Drug Type Small molecule drug |
Synonyms (3beta,5alpha,7beta)-3,7-Dihydroxyandrostan-17-one, 7beta-OH-Epia, 7β-hydroxy-epiandrosterone + [5] |
Target |
Mechanism GR antagonists(Glucocorticoid receptor antagonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC19H30O3 |
InChIKeyVFPMCLQMAUVEHD-UCPSWNCLSA-N |
CAS Registry25848-69-5 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Alzheimer Disease | Phase 2 | IN | 01 Jul 2006 | |
Alzheimer Disease | Phase 2 | SE | 01 Jul 2006 | |
Alzheimer Disease | Phase 2 | GB | 01 Jul 2006 | |
Rheumatoid Arthritis | Phase 1 | GB | - | |
Inflammatory Bowel Diseases | Preclinical | GB | - | |
Inflammatory Bowel Diseases | Preclinical | - | - | |
Psoriasis | Preclinical | GB | - | |
Psoriasis | Preclinical | - | - |